Supernus Pharmaceuticals (SUPN) Financial Statements & Analysis

Supernus Pharmaceuticals (SUPN) Income Statement

Supernus Pharmaceuticals reported revenue of $718.95M in fiscal 2025 (fiscal year ended Dec 31, 2025), up 8.6% from $661.82M a year earlier. Supernus Pharmaceuticals posted a net loss of $38.55M, compared with net income of $73.86M a year earlier. Gross margin was 89.6% and operating margin -8.7%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $219.06M, up 32.4% from the same quarter a year earlier.

Supernus Pharmaceuticals Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Supernus Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Revenue & Gross Profit
Revenue	718.95	661.82	607.52	667.24	579.78	520.40	392.76	408.90	302.24
Cost of Revenue	180.80	77.91	83.78	87.22	75.06	52.46	16.66	15.36	15.22
Gross Profit	644.39	583.91	523.74	580.02	504.71	467.94	376.10	393.54	287.02
Operating Expenses
Research & Development	106.24	108.80	91.59	74.55	90.47	75.96	69.10	89.21	49.58
Selling, General & Administrative	422.94	321.58	336.36	377.22	304.76	200.68	158.43	159.89	137.91
Operating Expenses	706.67	508.36	510.34	533.89	418.69	294.24	227.52	249.10	187.48
Operating Income	-62.28	75.56	13.40	46.12	86.03	173.70	148.57	144.44	99.54
Other Income/Expense
Interest Income	13.25	16.20	10.45	21.69	10.22	18.70	21.62	13.84	2.65
Interest Expense	0.00	0.00	2.42	-7.07	-23.42	23.75	22.71	18.11	1.57
Other Income/Expense	13.25	6.11	-18.67	14.62	-12.85	-5.05	-1.08	-4.27	1.08
Income
Income Before Tax	-49.03	97.87	2.77	60.74	73.18	168.65	147.49	140.18	100.62
Income Tax Expense	-10.48	24.01	1.45	0.03	19.75	41.70	34.43	29.18	43.33
Net Income	-38.55	73.87	1.32	60.71	53.42	126.95	113.06	110.99	57.28
Net Income - Continuous Operations	-38.55	73.87	1.32	60.71	53.42	126.95	113.06	110.99	57.28
Net Income - Discontinued Operations	-	-	-	-	-	-	-	-	-
EBITDA	117.32	178.28	90.04	131.16	112.09	210.54	180.42	151.51	107.67
EBIT	25.76	97.87	5.18	45.61	79.50	175.60	-	-	-
Depreciation & Amortization	91.56	77.98	82.39	85.54	32.60	18.14	10.23	7.06	8.13
Earnings Per Share
Basic EPS	-1.00	1.00	-	1.00	1.00	2.00	2.00	2.00	1.00
Diluted EPS	-1.00	1.00	-	1.00	1.00	2.00	2.00	2.00	1.00
Basic Shares Outstanding	56.45	55.10	54.54	53.67	53.10	52.62	52.41	51.99	50.76
Diluted Shares Outstanding	56.45	55.96	55.51	61.68	54.36	53.69	53.82	54.10	53.30

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Supernus Pharmaceuticals Financial Statements

What was Supernus Pharmaceuticals's revenue in fiscal 2025?

Supernus Pharmaceuticals reported revenue of $718.95M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was up 8.6% from $661.82M a year earlier.

Is Supernus Pharmaceuticals profitable?

No. Supernus Pharmaceuticals reported a net loss of $38.55M in fiscal 2025. In fiscal 2024 it earned $73.86M.

What is Supernus Pharmaceuticals's operating margin?

Supernus Pharmaceuticals's operating income was −$62.28M on revenue of $718.95M in fiscal 2025, an operating margin of -8.7%, compared with 11.4% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition